Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
出版年份 2018 全文链接
标题
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 24, Issue 2, Pages 179-194
出版商
Baishideng Publishing Group Inc.
发表日期
2018-01-14
DOI
10.3748/wjg.v24.i2.179
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
- (2017) Xiaoxin X. Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pathology of non-alcoholic fatty liver disease
- (2017) Pierre Bedossa LIVER INTERNATIONAL
- Non-alcoholic fatty liver disease: A sign of systemic disease
- (2017) Isabella Reccia et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Induction of Steatohepatitis (NASH) with Insulin Resistance in Wild-type B6 Mice by a Western-type Diet Containing Soybean Oil and Cholesterol
- (2017) Janin Henkel et al. MOLECULAR MEDICINE
- Targeting nuclear receptors for the treatment of fatty liver disease
- (2017) Naoki Tanaka et al. PHARMACOLOGY & THERAPEUTICS
- Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation
- (2017) Da-Gang Zhang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- GLP-1 and weight loss: unraveling the diverse neural circuitry
- (2016) Scott E. Kanoski et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
- (2016) Yaron Rotman et al. GUT
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
- (2016) Amon Asgharpour et al. JOURNAL OF HEPATOLOGY
- C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
- (2016) Khalidur Rahman et al. LABORATORY INVESTIGATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice
- (2016) Fahrettin Haczeyni et al. Obesity
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Effect of Weight Loss on Magnetic Resonance Imaging Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis
- (2015) Niraj S. Patel et al. Clinical Gastroenterology and Hepatology
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop
- (2015) Arun J. Sanyal et al. HEPATOLOGY
- Bile acids: emerging role in management of liver diseases
- (2015) Amon Asgharpour et al. Hepatology International
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice
- (2015) Tamiris Lima Rachid et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Liraglutide: A New Option for the Treatment of Obesity
- (2015) Wesley A. Nuffer et al. PHARMACOTHERAPY
- The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects
- (2014) Rémy Hanf et al. Diabetes & Vascular Disease Research
- The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice
- (2014) Michal Pawlak et al. HEPATOLOGY
- Beyond intestinal soap—bile acids in metabolic control
- (2014) Folkert Kuipers et al. Nature Reviews Endocrinology
- Overactivation of Intestinal SREBP2 in Mice Increases Serum Cholesterol
- (2014) Ke Ma et al. PLoS One
- Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology
- (2014) Wen Liang et al. PLoS One
- Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
- (2013) Jason R. Clapper et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Bile acid receptors in non-alcoholic fatty liver disease
- (2013) Yuanyuan Li et al. BIOCHEMICAL PHARMACOLOGY
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Immune and inflammatory pathways in NASH
- (2013) Michal Ganz et al. Hepatology International
- Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
- (2013) Rachel H. McMahan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype
- (2013) Geoffrey C. Farrell et al. LIVER INTERNATIONAL
- Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
- (2013) Yongjie Ma et al. PHARMACEUTICAL RESEARCH
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
- (2011) Jamie E. Mells et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- A position statement on NAFLD/NASH based on the EASL 2009 special conference
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Liraglutide
- (2010) Daniel J. Drucker et al. NATURE REVIEWS DRUG DISCOVERY
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
- (2009) Stefano Fiorucci et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent
- (2008) Laura H. Tetri et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
- (2008) B. Kong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
- (2007) Frank J. Gonzalez et al. TOXICOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started